progranulin (ALPHA-0602) / Alpha Cognition - LARVOL DELTA

UMass Chan Medical School Professor of Neurology at Fen-Biao Gao explores how frontotemporal dementia — the syndrome affecting Bruce Willis and which usually affects people under the age of 60 — changes the brain and how research is untangling FTD's genetic causes (Being Patient) - "Around 55 million people worldwide suffer from dementia such as Alzheimer's disease. Recently, the actor Bruce Willis was diagnosed with frontotemporal dementia, or FTD, a rare type of dementia that typically affects people ages 45 to 64....we collaborated with neurologist Bruce Miller and generated the first stem cell lines from FTD patients with mutations in progranulin and C9orf72."

Alpha Cognition Announces Marketed Offering (GlobeNewswire) - "Alpha Cognition Inc...is pleased to announce it has commenced a marketed public offering (the 'Offering') of units (the 'Units') for up to $10 million....The Over-Allotment Option may be exercised in whole or in part to purchase Common Shares, Warrants or Units as determined by the Agents upon written notice to the Company at any time up to 30 days following the closing date of the Offering. The Offering will be conducted pursuant to the Company’s Canadian base shelf prospectus dated February 24, 2022 (the 'Base Shelf Prospectus')....The Company intends to use the net proceeds of the Offering towards clinical development and marketing of its Alpha-1062 and Alpha-0602 formulations and for working capital and general corporate purposes."

Commercial • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders

Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update (Businesswire) - “Mild to Moderate Dementia of the Alzheimer’s Type: ALPHA-1062 (galantamine benzoate) prodrug, delayed release oral tablet: Alpha Cognition has initiated pivotal trials to demonstrate bioequivalence to the FDA-assigned reference listed drug...The Company plans to share topline results from the study in Q2 2022. Alpha Cognition intends to meet with the FDA to discuss the ongoing clinical development of ALPHA-1062 and a proposed Alzheimer’s disease tolerability and dosing trial…Pending regulatory feedback, the plan would be to initiate this study in late Q2 2022, with top line results expected in 2023….Research and development (R&D) expenses were $2.7 million for the three months ended December 31, 2021…R&D expenses increased in 2021 primarily due to the additional costs associated with advancing ALPHA-1062 and ALPHA-0602 clinical and preclinical studies.”

Clinical data • Commercial • FDA event • New trial • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders

Alpha Cognition Announces Director Change and Stock Option Grant (Businesswire) - “…Dr. Sancilio. Dr. O’Gorman commented: ‘We are accelerating the ALPHA-0602 progranulin pre-clinical study and are on track to release data in the first quarter of 2022. The Company is also excited to complete a pivotal relative bioavailability study of ALPHA-1062, a proprietary, delayed release oral tablet formulation designed to treat mild to moderate Alzheimer’s Disease. This single set of trials, if successful, will allow the Company to submit an NDA for ALPHA-1062 in the second half of 2022.’”

NDA • Preclinical • Alzheimer's Disease • CNS Disorders

Alpha Cognition Announces Director Change and Stock Option Grant (Businesswire) - '"We are accelerating the ALPHA-0602 progranulin pre-clinical study and are on track to release data in the first quarter of 2022. The Company is also excited to complete a pivotal relative bioavailability study of ALPHA-1062, a proprietary, delayed release oral tablet formulation designed to treat mild to moderate Alzheimer’s Disease. This single set of trials, if successful, will allow the Company to submit an NDA for ALPHA-1062 in the second half of 2022.'"

IND • Preclinical • Alzheimer's Disease • CNS Disorders

[VIRTUAL] Alpha Cognition, Inc. (BIO 2021) - "ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • Dementia • Gastrointestinal Disorder • Gene Therapies

Alpha Cognition Inc. announces granted EU Patents and Orphan Drug Designation for its progranulin platform (PRNewswire) - “Alpha Cognition…announced today it has been granted two EU patents (EP2249861A1 and EP3009143A1) relating to the treatment of neurodegenerative diseases using progranulin. Additionally, the FDA, has granted ACI Orphan Drug Designation for its progranulin product platform for the treatment of amyotrophic lateral sclerosis (ALS)….ACI is developing a specific form of progranulin, called Alpha-602, for the treatment of ALS patients.”

Orphan drug • Patent • Amyotrophic Lateral Sclerosis • CNS Disorders • Proteinopathy